Major R&D Pipeline: 3ADCs

DS-3201 Ph1: Efficacy results ATL a,c (N=14) Best Percent Change From Baseline in Sum of Area in Target Lesions All PTCLa Parameter (N=44) Best response, n (%) CR 12 (27.3) 4 (28.6) PR 12 (27.3) 4 (28.6) SD 5 (11.4) 2 (14.3) PD 8 (18.2) NE 1 (2.3) Not done 6 (13.6) ORR, n (%) 95% CI 24 (54.5) 38.8-69.6 3 (21.4) 0 (0) 1 (1.7) 8 (57.1) 28.9-82.3 DOR, median, weeks 56.0 (95% CI) (44.43, -) (6.14,-) TTR, median, weeks 8.14 (range) (4.1-24.1) 8.14 (7.3-84.1) PFS, median, weeks (95% CI) 52 (16.14, -) (8.14, -) Best % Change in Sum of Area From Baseline 100- 80 +1 +2 60 * 40 20 20 -20 * -40 -60 CR ✓ CRu PR SD Relapse/PD Daiichi-Sankyo -80 -100 *, ATL; +1, 146.9% increase from baseline; +2, 123.6% increase from baseline CR, complete response; CRu, complete response unconfirmed; PD, progressive disease; PR, partial response; SD, stable disease Data cutoff: 2 November 2020. Median follow-up times: PTCL, 19.93 (range, 3.1-68.1) weeks; ATL, 23.07 (range, 3.3-125) weeks. CR, complete response; DOR, duration of response; ORR, overall response rate; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease; TCL, T-cell lymphoma; TTR, time to first response. a For PTCL, 42 patients were treated with 200 mg, and 2 were treated with 150 mg. For ATL, 12 patients were treated with 200 mg, and 2 were treated with 150 mg. c Consists of 7 patients with acute and 7 patients with lymphomatous subtypes. Demonstrated ≥50% ORR and trend for durability of response in relapsed/refractory PTCL and ATL patients who have limited treatment options 24

View entire presentation